Corcept Therapeutics

CORT

Market cap $8.3B

Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.

Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to its preference for exclusive partnerships, causing some market confusion. CORT management and sell-side analysts confirm Curant Health is smoothly processing all new prescription growth, ensuring continuity.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for relacorilant to treat patients with platinum-resistant ovarian cancer. Corcept's MAA submission i.

Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.

ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to therapy, and comprehensive support to help patients and caregivers navigate the complexities of treatment. Patients will now benefit from Curant Rare's proven high-touch care model, designed to ensure timely access to medication, address treatment barriers such as insurance and financial concerns, and.

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

My September quarter EPS forecast of $0.29 for Corcept could meaningfully beat analyst projections of $0.17. Approval of the company's Relacorilant medication by the FDA will essentially resolve any generic threat of its current medication, Korlym. Corcept's patient base has increased from about 10,000 to over 1 million hard-to-treat diabetics.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 European Society for Medical Oncology.

These companies are expected to continue growing revenue at a rapid pace through 2027.

CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.